Ranibizumab is Ranibizumab injection, this product has a certain efficacy in the treatment of macular degeneration, but there are individual differences in efficacy, and should be used under the guidance of a doctor. Ranibizumab injection has a certain effect in the treatment of age-related (neovascularization) wet macular degeneration, but the efficacy of the treatment depends on the extent of the disease, the timing of the treatment and personal constitution and other factors, there are individual differences. Adverse reactions seen with Ranibizumab Injection include nasopharyngitis, influenza, anemia, anxiety, headache, stroke, endophthalmitis, vitritis, vitreous detachment, retinal hemorrhage, visual disturbances, ophthalmoplegia, and conjunctival hemorrhage. The drug is contraindicated in people who are allergic to the product, people with eye or periocular infections, and people with active intraocular inflammation. Specific use is subject to medical advice.